CytoDyn (OTCMKTS:CYDY – Get Free Report) is projected to issue its Q4 2026 results after the market closes on Wednesday, July 29th. Analysts expect CytoDyn to post earnings of ($0.05) per share for the quarter. Parties can check the company’s upcoming Q4 2026 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:00 PM ET.
CytoDyn Trading Down 1.0%
OTCMKTS:CYDY opened at $0.20 on Wednesday. The stock has a market capitalization of $279.58 million, a price-to-earnings ratio of -6.77 and a beta of 1.16. The firm has a fifty day simple moving average of $0.28 and a two-hundred day simple moving average of $0.28. CytoDyn has a 12 month low of $0.20 and a 12 month high of $0.40.
CytoDyn Company Profile
CytoDyn Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company’s lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.
In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies.
Further Reading
- Five stocks we like better than CytoDyn
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
